nie no faktycznie ciężko jest zrozumieć zdanie "tamoxifen, but not raloxifene, significantly reduced IGF-I levels by 25.6%"... wrzucając w translate.google.pl "tamoksyfen, ale nie raloksyfenu, znacząco zmniejszył poziom IGF-I o 25.6%"
[...] moze odwrocic poczatkowe gyno. Ludzie wala dawki od 0.5 mg do 2.5mg. Druga szkola mowi ze jesli sie juz pojawi gino to lepiej dzialja sermy tamoxifen lub nowszy wytwor - raloxifene (ponoc nalepszy na gino). Ostatnio jak mnie napadlo (powiekszony gruczol pod sutkiem plus duza bolesnosc nawet przy codziennym myciu) to tydzien na tamoxie [...]
[...] limited. Dihydrotestosterone, a non-aromatizable androgen, has been used in patients with prolonged pubertal gynecomastia with good response rates. SERMs are tamoxifen and raloxifene can help reduce the amount of breast tissue, even though they are not ready to completely dispense with the issue . Tamoxifen, an estrogen antagonist, is eوٴective [...]
[...] is most effective when done within the first two years after the start of male breast enlargement. Selective estrogen receptor modulators (SERMs) such as tamoxifen, raloxifene, and clomifene may be beneficial in the treatment of gynecomastia but are not approved by the Food and Drug Administration for use in gynecomastia. Clomifene seems [...]
Przy 20mg było tak: Results: Tamoxifen, but not raloxifene, significantly reduced IGF-I levels by 25 {+/-} 6% (P < 0.01) and increased SHBG levels by 20 {+/-} 7% (P < 0.05) at the higher therapeutic dose.
Patients and Intervention: Ten healthy men were randomized to 2-wk sequential treatment with tamoxifen (10 and 20 mg/d) and raloxifene (60 and 120 mg/d), with a 2-wk intervening washout period. Main Outcome Measures: We measured the GH response to arginine and circulating levels of IGF-I, LH, FSH, testosterone, and SHBG. Results: tamoxifen, but [...]
[...] 1,5 roku i nie zaobserwowano rzadnych skutkó ubocznych "Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene). RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was [...]
[...] gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene). RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was [...]
[...] a SERM, is used for therapy of osteoporosis in both sexes. Its neuroendocrine effects in men are poorly understood. Objective: The aim was to compare the impact of raloxifene and tamoxifen on GH-IGF-I and gonadal axes in healthy men. Design: We conducted a randomized, open-label crossover study. Patients and Intervention: Ten healthy [...]
[...] chore u których występuje ten objaw, powinny zachować ostrożność w czasie prowadzenia pojazdów i obsługi urządzeń mechanicznych w ruchu. Preparaty Fulvestrant Raloksyfen raloxifene antiosteoporoticum G03XC Działanie: Wybiórczy modulator receptora estrogenowego (selective estrogen receptor modulator - SERM) należący do pochodnych [...]
[...] did not occur. It is concluded that tamoxifen is a promising alternative to the surgical treatment of gynaecomastia. PMID: 6489180 " "Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. Department of Pediatrics, University of Ottawa, Ontario, Canada. [email protected] OBJECTIVES: To [...]
[...] Side-effects did not occur. It is concluded that tamoxifen is a promising alternative to the surgical treatment of gynaecomastia. PMID: 6489180 " “Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. Department of Pediatrics, University of Ottawa, Ontario, Canada. [email protected] OBJECTIVES: To [...]
[...] czy preparatów SERM w trakcie redukcji nie rozwiąże problemu. Objętościowe treningi aerobowe wcale nie muszą być skuteczne w redukcji tkanki tłuszczowej. Referencje, badania: R.E. Van Pelt „Estrogen or raloxifene during postmenopausal weight loss: Adiposity and cardiometabolic outcomes” https://onlinelibrary.wiley.com/doi/full/10.1002/oby.20653